PHAXIAM Therapeutics Company Profile, Contacts & Intelligence

PHAXIAM Therapeutics Overview

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Headquarters

Rockefeller, Fr

Website

erytech.com

Industry

Biotechnology

Founded

2004

Stock Symbol

PHXM

PHAXIAM Therapeutics Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

PHAXIAM Therapeutics People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

PHAXIAM Therapeutics Workforce Composition

Seniority breakdown across 3 visible profiles.

Compare Similar Companies to PHAXIAM Therapeutics

Explore companies in related markets and compare their industry and employee estimates.